<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101235741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32200</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-title-group>
<journal-title>American journal of medical genetics. Part A</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28425223</article-id>
<article-id pub-id-type="pmc">5444958</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.38235</article-id>
<article-id pub-id-type="manuscript">NIHMS861680</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Three Families with Mild PMM2-CDG and Normal Cognitive Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vals</surname>
<given-names>Mari-Anne</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morava</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teeäär</surname>
<given-names>Kai</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zordania</surname>
<given-names>Riina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pajusalu</surname>
<given-names>Sander</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lefeber</surname>
<given-names>Dirk J.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Õunap</surname>
<given-names>Katrin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia</aff>
<aff id="A2"><label>2</label>Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia</aff>
<aff id="A3"><label>3</label>Children’s Clinic, Tartu University Hospital, Tartu, Estonia</aff>
<aff id="A4"><label>4</label>Department of Pediatrics, Tulane University Medical School, New Orleans, LA</aff>
<aff id="A5"><label>5</label>Center for Metabolic Diseases, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium</aff>
<aff id="A6"><label>6</label>Tallinn Children’s Hospital, Tallinn, Estonia</aff>
<aff id="A7"><label>7</label>Translational Metabolic Laboratory, Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands</aff>
<author-notes>
<corresp id="FN1">Correspondence: MA Vals, Department of Clinical Genetics, United Laboratories, Tartu University Hospital, 2 L. Puusepa Street, Tartu 51014, Estonia. Tel: (+372) 7 319 491; <email>mari-anne.vals@kliinikum.ee</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2018</year>
</pub-date>
<volume>173</volume>
<issue>6</issue>
<fpage>1620</fpage>
<lpage>1624</lpage>
<!--elocation-id from pubmed: 10.1002/ajmg.a.38235-->
<abstract>
<p id="P1">Congenital disorders of glycosylation (CDG) are caused by defective glycosylation of proteins and lipids. PMM2-CDG is the most common subtype among the CDG. The severity of PMM2-CDG is variable. Patients often have a recognizable phenotype with neurological and multisystem symptoms that might cause early death. We report six patients from three families who are diagnosed with a clinically mild PMM2-CDG and have normal cognitive development. All these patients had delayed gross motor skills with mild-to-moderate neurological findings. Cerebellar hypoplasia was detected in all siblings for whom brain MRI was performed. In 5/6 children the Wechsler Intelligence Scale for Children (WISC) showed normal cognitive development with full scale IQ scores ranging from borderline to average. Four patients were diagnosed with PMM2-CDG at the age of 8 years or later as their neurological symptoms were quite mild and they had been able to participate in regular school programs. We report patients with p.Val231Met/p.Arg239Trp and p.Ile120Thr/p.Gly228Cys genotypes which may cause milder variants of PMM2-CDG.</p>
</abstract>
<kwd-group>
<kwd>PMM2-CDG</kwd>
<kwd>congenital disorders of glycosylation</kwd>
<kwd>mild phenotype</kwd>
<kwd>cerebellar hypoplasia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>